| Bioactivity | NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI)[1]. |
| Invitro | NF-κB-IN-8 (化合物 L26) (10 μM) 抑制 64.30% 的 ALP 活性[1]。NF-κB-IN-8 (1-10 μM, 24 h) 抑制 RAW 264.7 细胞中 IL-6 和 TNF-α 的表达[1]。NF-κB-IN-8 (0-50 μM) 抑制 LPS 与 MD-2 的结合，通过 ELISA 检测[1]。NF-κB-IN-8 (50 μM，过夜) 抑制 RAW264.7 细胞中 LPS/MD-2/TLR4 聚合物的形成[1]。 Western Blot Analysis[1] Cell Line: |
| In Vivo | NF-κB-IN-8 (化合物 L26) (5 mg/kg，灌胃给药) 减轻 LPS 诱导的小鼠急性肺损伤[1]。NF-κB-IN-8 (1000 和 1500 mg/kg，灌胃给药) 对小鼠毒性低，且安全[1]。NF-κB-IN-8 (0 mg/kg, 大鼠) 显示出 T1/2: 4.2 h, Cmax: 163.288 μg/L[1]。 Animal Model: |
| Name | NF-κB-IN-8 |
| Formula | C24H21N3O3 |
| Molar Mass | 399.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li X, et al. Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2. Eur J Med Chem. 2023 Apr 5;252:115289. |